CheckMate‑9DW Trial Summary
Study Design & Context
Type: Phase III, randomized, open-label clinical trial (NCT04039607) Population: ~668 adults with previously untreated, unresectable hepatocellular carcinoma (HCC) Arms: Experimental: Nivolumab (Opdivo) 1 mg/kg + Ipilimumab (Yervoy) 3 mg/kg every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks Comparator: Investigator’s choice of lenvatinib or sorafenib monotherapy Primary Endpoint: Overall Survival (OS) Secondary Endpoints: Objective Response Rate (ORR), Duration of Response (DOR), Time to Symptom Deterioration (TTSD)
Key Results
Overall Survival: Median OS: 23.7 months with nivolumab/ipilimumab vs 20.6 months with lenvatinib or sorafenib Hazard Ratio (HR): 0.79 (95% CI: 0.65–0.96); p = 0.018 — statistically significant survival benefit Objective Response Rate: 36% (95% CI: 31–42) for nivolumab/ipilimumab vs 13% (95% CI: 10–17) with TKIs Complete Response (CR) rate: 7% vs 2% Median Duration of Response: 30.4 months vs 12.9 months Symptom Deterioration: Nivolumab/ipilimumab reduced risk of symptom deterioration by 24% compared to TKIs
Safety Profile
The safety of nivolumab/ipilimumab was consistent with known profiles—no new safety concerns were identified Immune-mediated adverse events occurred in 58% of patients, with 28% experiencing Grade 3–4 events Most common severe events: hepatitis (15%), diarrhea/colitis (5%), and rash (4%) TKI arm: notable Grade 3–4 events included hypertension, proteinuria, diarrhea, and hand–foot skin reaction
Clinical Implications
CheckMate‑9DW demonstrates that first-line combination immunotherapy with nivolumab + ipilimumab delivers both a statistically significant improvement in overall survival and a substantially higher response rate compared with first-generation tyrosine kinase inhibitors (lenvatinib or sorafenib). The durable responses (median DOR > 30 months) are particularly notable in advanced HCC.
Given its manageable safety profile and meaningful efficacy benefit, this regimen is positioned to become a new standard of care for unresectable HCC. The FDA has accepted the supplemental BLA, with a Prescription Drug User Fee Act action date set for April 21, 2025.